Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bordignon, C. et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 270, 470–475 (1995).
Blaese, R.M. et al. T lymphocyte–directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270, 475–480 (1995).
Kohn, D.B. et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Med. 1, 1017–1023 (1995).
Hoogerbrugge, P.M. et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 3, 179–183 (1996).
Onodera, M. et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91, 30–36 (1998).
Ochs, H.D. et al. Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. Blood 80, 1163–1171 (1992).
Parkman, R., Gelfand, E.W., Rosen, F.S., Sanderson, A. & Hirschhorn, R. Severe combined immunodeficiency and adenosine deaminase deficiency. N. Engl. J. Med. 292, 714–719 (1975).
Hirschhorn, R., Roegner, M.V., Kuritsky, L. & Rosen, F.S. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J. Clin. Invest. 68, 1387–1393 (1981).
Kohn, D.B. et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nature Med. 4, 775–780 (1998).
Arredondo, V.F., Santisteban, I., Daniels, S., Toutain, S. & Hershfield, M.S. Adenosine deaminase deficiency: Genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am J Hum Genet 63, 1049–1059 (1998).
Bordignon, C. et al. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Hum. Gene Ther. 4, 513–520 (1993).
About this article
Nature Reviews Drug Discovery (2019)
Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry
Gene Therapy (2017)
Current Pediatrics Reports (2015)
Preclinical Demonstration of Lentiviral Vector-mediated Correction of Immunological and Metabolic Abnormalities in Models of Adenosine Deaminase Deficiency
Molecular Therapy (2014)
Journal of Inherited Metabolic Disease (2014)